Table 1.

Median autoantibody concentrations split by center

AutoAb Against:	Overall			Calgary			Malmö			POTS Calgary vs. Malmö	Control Calgary vs. Malmö
	POTS (n=116)	Control (n=81)	p-value	POTS (n=52)	Control (n=16)	p-value	POTS (n=64)	Control (n=65)	p-value	p-value	p-value
AT1R	12.8 (8.9–22.8)	10.9 (7.5–18.9)	0.065	15.0 (11.6–41.9)	13.9 (10.2–37.4)	0.761	10.4 (7.9–17.1)	10.4 (6.8–16.9)	0.486	0.001	0.017
ETAR	9.9 (7.5–15.8)	8.8 (5.8–13.4)	0.081	13.3 (8.6–21.5)	11.4 (8.0–20.0)	0.745	9.1 (6.5–14.2)	8.6 (5.3–13.1)	0.486	0.002	0.044
α1-AR	16.0 (12.6–26.4)	14.0 (11.3–24.6)	0.195	19.7 (13.2–29.0)	16.0 (12.3–29.8)	0.573	15.2 (10.6–23.6)	13.4 (10.5–24.5)	0.797	0.013	0.182
α2-AR	11.7 (9.3–15.3)	11.6 (9.4–15.8)	0.868	10.5 (8.7–15.2)	11.2 (9.3–17.3)	0.553	12.5 (10.0–15.6)	11.8 (9.4–15.8)	0.423	0.037	0.704
β1-AR	5.3 (4.3–7.7)	5.6 (4.0–7.8)	0.863	6.1 (4.3–10.5)	6.9 (5.2–32.9)	0.318	5.3 (3.9–6.4)	5.3 (4.0–7.5)	0.812	0.015	0.017
β2-AR	5.2 (3.8–7.50	5.1 (3.6–8.0)	0.822	5.5 (4.1–10.4)	7.8 (4.9–10.7)	0.236	4.8 (3.6–7.2)	4.9 (3.3–7.5)	0.949	0.042	0.011
M1R	2.0 (1.5–2.8)	2.0 (1.5–3.1)	0.831	2.3 (1.8–3.3)	3.1 (1.6–3.3)	0.548	1.9 (1.4–2.4)	1.9 (1.5–2.6)	0.543	0.002	0.063
M2R	3.0 (2.3–4.4)	2.6 (2.0–4.2)	0.226	4.2 (3.1–5.6)	4.7 (3.4–9.5)	0.294	2.6 (1.6–3.3)	2.3 (1.9–3.5)	0.895	<0.001	<0.001
M3R	7.7 (5.8–9.6)	8.1 (6.7–10.9)	0.053	6.2 (5.1–8.2)	7.5 (5.5–9.1)	0.256	8.2 (6.8–10.2)	8.5 (7.0–11.1)	0.801	<0.001	0.122
M4R	7.8 (6.2–10.4)	7.5 (6.5–10.1)	0.890	7.0 (5.7–11.3)	8.5 (6.0–11.6)	0.378	8.3 (6.7–9.3)	7.5 (6.6–9.8)	0.262	0.176	0.413
M5R	6.0 (4.7–7.7)	5.7 (4.9–7.0)	0.861	6.1 (4.7–8.3)	7.1 (5.3–9.2)	0.393	5.9 (4.8–7.1)	5.5 (4.9–6.8)	0.772	0.242	0.042

AT1R: angiotensin II receptor type 1; α1-AR: alpha-1 adrenergic receptors; α2-AR: alpha-2 adrenergic receptors; β1-AR: beta-1 adrenergic receptors; β2-AR: beta-2 adrenergic receptors; ETAR: endothelin receptor A; M1R-M5R: muscarinic receptor 1 to 5; POTS: Postural Orthostatic Tachycardia Syndrome.